Neurotron specializes in advanced neurodiagnostic technologies, particularly through its flagship device, the Neurometer® CPT®. This innovative device allows for painless evaluations of sensory nerve function by assessing small unmyelinated (C), small myelinated (Aδ), and large myelinated (Aβ) nerve fibers at various cutaneous sites. The Neurometer® CPT® is notable for its ability to detect both hypoesthetic and hyperesthetic abnormalities, making it a valuable tool for diagnosing a range of neuropathic conditions, including diabetes-related nerve damage, carpal tunnel syndrome, and spinal injuries. With over 800 peer-reviewed publications supporting its efficacy, the device has been widely adopted in clinical settings since its FDA clearance in 1986, with more than a million tests conducted globally.

In addition to its core diagnostic capabilities, Neurotron offers a suite of products and software designed to enhance the evaluation process. The Neuval® CPT® software complements the Neurometer® by providing automated analysis, storing patient results, and generating reports based on established norms. The technology is versatile, applicable across various medical fields such as orthopedics, neurology, and oncology, and is also utilized in laboratory animal research and pharmaceutical development. The device's non-invasive nature, combined with its resistance to external factors like skin temperature and electromagnetic interference, positions it as a reliable alternative to traditional electrodiagnostic methods.

United States

Neurotron is a medical devices company that specializes in Neurometer CPT electrodiagnostic sensory nerve conduction threshold (sNCT) testing equipment.

Neurotron

Company Details